Table 7 Univariate and multivariate cox regression analysis of HECW1 expression classifier and clinical characteristics with overall survival and progression-free survival in the validation cohort (n = 120) (3:2ratio)

Age (≥60y vs < 60y)

1.535 (0.690–3.417)

0.294

2.417 (1.052–5.554)

0.038

Gender (Male vs Female)

1.274 (0.542–2.994)

0.579

0.807 (0.316–2.061)

0.654

WHO/ISUP Grading (III-IV vs I-II)

3.064 (1.396–6.723)

0.005

1.029 (0.418–2.536)

0.95

3.484 (1.534–7.912)

0.003

1.180 (0.477–2.923)

0.72

TNM stage (III-IV vs I-II)

5.160 (2.272–11.719)

< 0.001

3.248 (1.171–9.011)

0.024

5.287 (2.292–12.195)

< 0.001

3.087 (1.052–9.060)

0.04

SSIGN (≥5 vs 1–4)

5.492 (2.135–14.130)

< 0.001

3.425 (1.025–11.443)

0.045

10.988 (3.921–30.795)

< 0.001

5.918 (1.383–9.060)

0.017

HECW1 (High vs Low)

13.743 (4.100–46.065)

< 0.001

7.480 (1.978–28.295)

0.003

21.144 (4.947–90.383)

< 0.001

10.613 (2.226–50.600)

0.003